Bayer Schering Pharma AG: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors

• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Bayer: PharmaVitae forecasts at a glance
• Strategic insight
  • (Untitled sub-section)

• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Product developments
• Deals and alliances
  • Technology deals

• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• Current corporate structure
  • Bayer Healthcare
  • Bayer MaterialScience
  • Bayer CropScience

• Bayer Healthcare business unit structure
  • Prescription pharmaceuticals
  • Consumer care
  • Animal health
  • Medical care (Diagnostics)

• M&A history
  • Acquisition of Roche Consumer Health AG (RCH)
  • Lanxess AG Spin-off
  • Divestment of US Plasma Products
  • Acquisition of Schering AG
  • Recent M&A promotes Bayer' s healthcare focus
  • M&A strategy

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14

• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Launch/core/expiry configuration, 2008 - 14

• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
  • Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Oncology
  • Nexavar

• Cardiovascular
  • Xarelto
  • Adalat

• Hematology
  • Kogenate

• Genitourinary
  • Mirena
  • Levitra
  • Yaz
  • Yasmin

• Central nervous system
  • Betaferon
  • MabCampath (MS)

• Infectious disease
  • Avelox

• Endocrine, metabolic and genetic disorders
  • (Untitled sub-section)

• Other
  • VEGF Trap-Eye

APPENDIX

• R&D pipeline
• References
• Abbreviations
• Exchange rates

TABLES

• Table: Bayer - PharmaVitae forecasts at a glance
• Table: Bayer key product developments, 2009
• Table: Bayer product deals and alliances, 2009
• Table: Bayer technology deals and alliances, 2009
• Table: Bayer M&A activity, 2009
• Table: Bayer company announcements, 2009
• Table: Bayer future product milestones, 2009 - 11
• Table: Bayer product portfolio overview ($m), 2002 - 08
• Table: Bayer product portfolio overview ($m), 2008 - 14
• Table: Bayer prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Bayer prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Bayer launch portfolio overview ($m), 2008 - 14
• Table: Bayer core portfolio overview ($m), 2008 - 14
• Table: Bayer expiry portfolio overview ($m), 2008 - 14
• Table: Bayer prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Bayer prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Bayer sales by business unit ($m), 2002 - 08
• Table: Bayer operating revenue/cost analysis ($m), 2002 - 08
• Table: Bayer operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Bayer operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Bayer operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Nexavar: overview
• Table: Nexavar: sales forecast ($m), 2008 - 14
• Table: Xarelto: overview
• Table: Xarelto: sales forecast ($m), 2008 - 14
• Table: Adalat: overview
• Table: Adalat: sales forecast ($m), 2008 - 14
• Table: Kogenate: overview
• Table: Kogenate: sales forecast ($m), 2008 - 14
• Table: Mirena: overview
• Table: Mirena: sales forecast ($m), 2008 - 14
• Table: Key players in the oral contraceptives market, 2008 - 14
• Table: Levitra: overview
• Table: Levitra: sales forecast ($m), 2008 - 14
• Table: Yaz: overview
• Table: Yaz: sales forecast ($m), 2008 - 14
• Table: Yasmin: overview
• Table: Yasmin: sales forecast ($m), 2008 - 14
• Table: Betaferon: overview
• Table: Betaferon: sales forecast ($m), 2008 - 14
• Table: MabCampath (MS): overview
• Table: MabCampath (MS): sales forecast ($m), 2008 - 14
• Table: Avelox: overview
• Table: Avelox: sales forecast ($m), 2008 - 14
• Table: Key players in the antibiotics market, 2008
• Table: Glucobay: overview
• Table: Glucobay: sales forecast ($m), 2008 - 14
• Table: VEGF Trap-Eye: overview
• Table: VEGF Trap-Eye: sales forecast ($m), 2008 - 14
• Table: Bayer' s R&D new molecular entity pipeline (Phase I - registration)
• Table: Bayer' s R&D life cycle management pipeline (Phase I - registration)
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Bayer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Bayer' s financial performance ($m), 2002 - 14
• Figure: Bayer AG corporate structure, 2002 - 14
• Figure: Bayer AG, key acquisitions and divestments, 2001 - 08
• Figure: Big Pharma peer set: rank by prescription pharma focus as % of total revenue, 2008 and 2014
• Figure: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Bayer SWOT analysis
• Figure: Current corporate structure
• Figure: Bayer Healthcare business unit structure by revenues, 2002 - 08, ($m)
• Figure: Bayer key M&A and divestment events, 2002 - 08
• Figure: Bayer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Bayer key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Bayer key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Bayer prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Bayer prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Bayer launch/core/expiry configuration ($m), 2008 - 14
• Figure: Bayer prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Bayer prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Bayer operating revenue/cost analysis ($m), 2002 - 14